Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company's cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
According to the company, GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. The European launch follows the CE Mark approval and positions Regentis to tap into a significant unmet need. The training program is expected to accelerate surgeon proficiency and confidence with the implant, which is designed to be eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled process.
Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, is intended to regenerate damaged or diseased tissue including inflamed cartilage and bone. For more details on the announcement, visit https://ibn.fm/QOWWK.
The company's forward-looking statements are subject to risks and uncertainties, as detailed in its SEC filings, including the Risk Factors section of its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. See http://IBN.fm/Disclaimer for full terms and disclaimers.
